Mission Statement

Corthera is a biopharmaceutical company committed to acquiring, developing and commercializing therapeutics in the acute care setting.

Relaxin

Corthera’s lead product candidate, relaxin, is a naturally occurring peptide hormone that acts as a systemic and targeted renal vasodilator.

Relaxin is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure.

In The News

November 10, 2008

Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera’s Relaxin in Acute Heart Failure

November 03, 2008

Top-Line Preliminary Data From Phase II/III Study of Corthera’s Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008

January 08, 2008

Corthera Initiates Phase II Clinical Trail of Relaxin in Acute Heart Failure